BML Investment Partners, L.P. Increases Stake in Aclaris Therapeutics to 9.9%

On April 27, 2026, BML Investment Partners, L.P. filed a Schedule 13G/A regarding its holdings in Aclaris Therapeutics, Inc. (ACRS). The filing reveals that BML Investment Partners now beneficially owns 13,950,000 shares of common stock, representing a 9.9% ownership stake in the company. This represents a significant increase from the previously reported zero shares and 0.0% ownership. The event triggering this filing occurred on April 23, 2026. The shares are held with shared voting and dispositive power among BML Investment Partners, L.P., its general partner BML Capital Management, LLC, and Braden M. Leonard, the managing member of the general partner. The filing was made under Rule 13d-1(c), indicating a passive investment intent, as the reporting persons certified that the securities were not acquired to influence or change the control of the issuer. The ownership percentage is based on 139,663,680 shares outstanding as disclosed by Aclaris Therapeutics in a recent proxy statement.